Article
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Cancer - 15 Mar 2020
Rubinstein Maria M, Hyman David M, Caird Imogen, Won Helen, Soldan Krysten, Seier Kenneth, Iasonos Alexia, Tew William P, O'Cearbhaill Roisin E, Grisham Rachel N, Hensley Martee L, Troso-Sandoval Tiffany, Sabbatini Paul, Guillen Joyce, Selcuklu S Duygu, Zimel Catherine, Torrisi Jean, Aghajanian Carol, Makker Vicky
Abstract excerpt
BACKGROUND: PI3K pathway activation is common in endometrial cancer. We evaluated the safety and efficacy of the dual PI3K/mTOR inhibitor, LY3023414, in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. METHODS: We conducted a single-arm phase 2 study of monotherapy LY3023414. Eligible patients had advanced endometrial cancer of any grade, prior management with 1-4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.